DrugPatentWatch Database Preview
Drugs in Development Information for VTP-27999
Email this page to a colleague
What is the development status for investigational drug VTP-27999?
VTP-27999 is an investigational drug.
There have been 18 clinical trials for VTP-27999.
The most recent clinical trial was a Phase 3 trial, which was initiated on January 21st 2019.
The most common disease conditions in clinical trials are Prostatic Neoplasms, Psoriasis, and Carcinoma, Transitional Cell. The leading clinical trial sponsors are Steba Biotech S.A., Vitae Pharmaceuticals, Inc., and STEBA France.
There are four US patents protecting this investigational drug and fifty-nine international patents.
Summary for VTP-27999
| US Patents | 4 |
| International Patents | 59 |
| US Patent Applications | 12 |
| WIPO Patent Applications | 4 |
| Japanese Patent Applications | 4 |
| Clinical Trial Progress | Phase 3 (2019-01-21) |
| Vendors | 32 |
Recent Clinical Trials for VTP-27999
| Title | Sponsor | Phase |
|---|---|---|
| ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study | Medpace, Inc. | Phase 3 |
| ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study | PrimeVigilance | Phase 3 |
| ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study | Steba Biotech S.A. | Phase 3 |
Clinical Trial Summary for VTP-27999
Top disease conditions for VTP-27999
Top clinical trial sponsors for VTP-27999
US Patents for VTP-27999
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| VTP-27999 | Get Started Free | Piperidine renin inhibitors | Vitae Pharmaceuticals, Inc. (Fort Washington, PA) | Get Started Free |
| VTP-27999 | Get Started Free | Salts of methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-2-(methylamino)-3-((R)-tetrahydro-2H-p- yran-3-yl)propylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate | Vitae Pharmaceuticals, Inc. (Fort Washington, PA) | Get Started Free |
| VTP-27999 | Get Started Free | Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors | Vitae Pharmaceuticals, Inc. (Fort Washington, PA) | Get Started Free |
| VTP-27999 | Get Started Free | Piperidine renin inhibitors | Vitae Pharmaceuticals, Inc. (Fort Washington, PA) | Get Started Free |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for VTP-27999
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| VTP-27999 | Argentina | AR057890 | 2025-11-14 | Get Started Free |
| VTP-27999 | Argentina | AR062797 | 2025-11-14 | Get Started Free |
| VTP-27999 | Austria | AT520690 | 2025-11-14 | Get Started Free |
| VTP-27999 | Austria | AT538092 | 2025-11-14 | Get Started Free |
| VTP-27999 | Australia | AU2006325322 | 2025-11-14 | Get Started Free |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
